These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 16121929)
1. [Oxaliplatin]. Furue H Gan To Kagaku Ryoho; 2005 Aug; 32(8):1195-202. PubMed ID: 16121929 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Culy CR; Clemett D; Wiseman LR Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137 [TBL] [Abstract][Full Text] [Related]
5. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243 [TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Bleiberg H Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611 [TBL] [Abstract][Full Text] [Related]
7. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627 [TBL] [Abstract][Full Text] [Related]
8. [Anaphylactic reaction to oxaliplatin--a case of colon cancer]. Sagawa T; Sato Y; Abe S; Okuda T; Araki N; Takahari D; Okamoto T; Takayama T; Kato J; Niitsu Y Gan To Kagaku Ryoho; 2006 Dec; 33(13):2093-6. PubMed ID: 17197761 [TBL] [Abstract][Full Text] [Related]
10. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin in the treatment of colorectal cancer. Kim GP; Erlichman C Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157 [TBL] [Abstract][Full Text] [Related]
12. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin. Lila AS; Kiwada H; Ishida T Biol Pharm Bull; 2014; 37(2):206-11. PubMed ID: 24492717 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L Oncology; 2004; 66(5):371-8. PubMed ID: 15331924 [TBL] [Abstract][Full Text] [Related]
14. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598 [TBL] [Abstract][Full Text] [Related]
15. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Khayat D; Gil-Delgado M; Antoine EC; Nizri D; Bastian G Oncology (Williston Park); 2001 Apr; 15(4):415-29; discussion 429-30, 433-4. PubMed ID: 11346931 [TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Wiseman LR; Adkins JC; Plosker GL; Goa KL Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744 [TBL] [Abstract][Full Text] [Related]
17. [Oxaliplatin: a first DACH-platinum in oncology]. Laadem A; Cvitkovic E Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908 [TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy. Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. Boku N; Ohtsu A; Hyodo I; Shirao K; Miyata Y; Nakagawa K; Tamura T; Hatake K; Tanigawara Y Jpn J Clin Oncol; 2007 Jun; 37(6):440-5. PubMed ID: 17656482 [TBL] [Abstract][Full Text] [Related]
20. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]